S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%S&P 500 5,235.18 +1.02%EUR/USD 1.0840 +0.21%GBP/USD 1.2710 +0.14%USD/JPY 149.50 −0.18%BRENT $82.40 −0.81%BTC $67,800 −0.21%GOLD $2,341 +0.55%NASDAQ 16,420.55 +0.74%
A daily business newspaper · Founded in 2026

Money Talk

Finance and markets: business, quotes, gold, energy and releases.

Huion Debuts Kamvas Pad 12 with PenTech 4.0 and Android 16

A year after entering the slate market, Huion is pivoting toward general-purpose utility with the Kamvas Pad 12. Unveiled in Los Angeles, the new 12.2-inch Android tablet targets creators who require a portable workstation that balances high-fidelity drawing capabilities with the flexibility of a traditional mobile operating system.

Huion Debuts Kamvas Pad 12 with PenTech 4.0 and Android 16
Photo: Bio & News

The device centers on the PW600C battery-free EMR pen, which utilizes the company’s latest PenTech 4.0 technology and attaches magnetically to the chassis. The screen features a 2400 x 1600 resolution with a 90Hz refresh rate, utilizing a 3:2 aspect ratio that favors document viewing and split-screen multitasking. To replicate the tactile experience of paper, Huion integrated its Canvas Glass 3.0, an anti-glare, anti-fingerprint surface designed to minimize eye strain during extended use.

Under the hood, the tablet runs Android 16, supported by an 8-core MediaTek Genio 720 processor. This hardware configuration is designed to handle demanding creative software, including preloaded applications such as Clip Studio Paint, HiPaint, and ibisPaint X. By combining specialized drawing hardware with a mobile OS, Huion positions the Kamvas Pad 12 as a hybrid tool intended for digital artists, students, and professionals who prioritize portability without sacrificing granular control over their creative workflow.

Share article
TelegramXFacebook

When reusing this material a link to Money Talk is required.

Comments (0)

Leave a comment

No comments yet. Be the first!